

PRESS RELEASE VII - 05/2021

Final Countdown: Prospect on PANBioRA activities in the last project year

After having successfully completed the second period in December 2020, the PANBioRA project is now in its final phase. The last project year will mainly focus on exploitation activities and the further commercialization of the PANBioRA device.

PANBioRA is a four-year “Research and Innovation Action” funded by the European Union’s Horizon 2020 programme aiming to develop a modular system using interdisciplinary techniques that will predict the patient-specific response to a given biomaterial and methods for analysing novel biomaterials. PANBioRA’s testing system will therefore provide an improved, faster, and cheaper assessment of biomaterials. The previous project period mainly focused on the integration of the PANBioRA device and the establishment of the connections between the different systems. Furthermore, the first version of the PANBioRA risk rating system based on Multiple Criteria Decision Making has been developed. Clinical samples were collected and tested, and initial steps of planning for the prototype’s commercialization have been taken. With conclusion of the second reporting period, the project received excellent feedback by the European Commission stating that “some of the specific research tasks have a very strong innovation potential which will be undoubtedly welcomed by the stakeholders involved in the risk management of new nano-biomaterials.”¹

One of the major challenges for the upcoming months will be the final integration of components to the main device, data collection from sensors and continuation opportunities for the project after the official ending in December 2021. The final phase in the project will furthermore concentrate on the exploitation of the gathered findings and possible patent applications. During the project’s fifth and last exploitation workshop on April 14th 2021, the consortium virtually exchanged in a collaborative work inputs and ideas to focus the roadmaps to exploitation and economic benefits of PANBioRA results.

During the last couple of months, the project has been actively presented at different occasions: events and workshops of other Horizon 2020 projects, e.g. [SENET](#) and [BrainTwin](#), a webinar organised by the Grand Est region in France, as well as the University of Strasbourg’s life science Doctoral School Days, offered engaging interactions.

Following a highly structured dissemination plan, the consortium is continuously working on further project outputs which will be shared in form of scientific papers and other publications.

Relevant publications in the last project period will be:

¹ European Commission (15/03/2021): General Project Review Consolidated Report





- [Reference method for off-line analysis of nitrogen oxides in cell culture media by an ozone-based chemiluminescence detector](#)
- [Biofunctionalization of 3D-printed silicone implants with immunomodulatory hydrogels for controlling the innate immune response: An *in vivo* model of tracheal defect repair](#)
- [PVA/gelatin-based hydrogel coating of nickel-titanium alloy for improved tissue-implant interface](#)
- [Reversed-engineered human alveolar lung-on-a-chip model](#)
- [Mitigating the foreign body response through 'immune-instructive' biomaterials](#)

In addition, PANBioRA consortium members will be present at different (virtual) events taking place in the next couple of months, e.g. SCSB conference, EUROOCS, Biointerfaces International, ESB 2021, TERMIS World Congress and many more. An updated overview on all the events planned to be attended in the last project period can be examined on the [project website](#).

For further information please visit www.panbiora.eu or follow PANBioRA on [Facebook](#), [LinkedIn](#), [Twitter](#) and check out our project video: [YouTube](#).

Project coordinator:

Scientific coordinator:

Dr. Nihal Engin Vrana | evrana@sparthamedical.eu |

Administrative coordinator:

Steinbeis 2i GmbH

Timo Doll | doll@steinbeis-europa.de | +49 721 93519141

PANBioRA is coordinated by Steinbeis 2i GmbH in cooperation with 16 partners: Spartha Medical (Scientific Coordinator), Dolmen Design and Innovation Limited, Biodevice Systems, Protobios, Elvsys SAS, Steinbeis Advanced Risk Technologies Institute doo Kragujevac, Steinbeis Advanced Risk Technologies GmbH, Commissariat A L'Énergie Atomique Et Aux Énergies Alternatives, Pro-active, Aalto-Korkeakoulusäätiö, Turgut Ozal Education SHA, The University of Nottingham, Agencia Estatal Consejo Superior de Investigaciones Científicas, Dublin City University, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Liège

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 760921.

